Product nameAnti-SIRT4 antibody - C-terminal
See all SIRT4 primary antibodies
DescriptionRabbit polyclonal to SIRT4 - C-terminal
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Human
Synthetic peptide within Human SIRT4 (C terminal). The exact sequence is proprietary. (Carrier-protein conjugated).
Database link: Q9Y6E7
- WB: HeLa whole cell extract.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.00
Preservative: 0.025% Proclin
Constituents: PBS, 20% Glycerol
Concentration information loading...
PurityImmunogen affinity purified
- Epigenetics and Nuclear Signaling
- Chromatin Modifying Enzymes
- Class III / Sir2 class
- Pathways and Processes
- Metabolic signaling pathways
- Energy transfer pathways
- Energy Metabolism
Our Abpromise guarantee covers the use of ab227930 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500 - 1/3000. Predicted molecular weight: 35 kDa.|
FunctionActs as NAD-dependent protein lipoamidase, ADP-ribosyl transferase and deacetylase. Catalyzes more efficiently removal of lipoyl- and biotinyl- than acetyl-lysine modifications. Inhibits the pyruvate dehydrogenase complex (PDH) activity via the enzymatic hydrolysis of the lipoamide cofactor from the E2 component, DLAT, in a phosphorylation-independent manner (PubMed:25525879). Catalyzes the transfer of ADP-ribosyl groups onto target proteins, including mitochondrial GLUD1, inhibiting GLUD1 enzyme activity. Acts as a negative regulator of mitochondrial glutamine metabolism by mediating mono ADP-ribosylation of GLUD1: expressed in response to DNA damage and negatively regulates anaplerosis by inhibiting GLUD1, leading to block metabolism of glutamine into tricarboxylic acid cycle and promoting cell cycle arrest (PubMed:16959573, PubMed:17715127). In response to mTORC1 signal, SIRT4 expression is repressed, promoting anaplerosis and cell proliferation. Acts as a tumor suppressor (PubMed:23562301, PubMed:23663782). Also acts as a NAD-dependent protein deacetylase: mediates deacetylation of 'Lys-471' of MLYCD, inhibiting its activity, thereby acting as a regulator of lipid homeostasis (By similarity). Controls fatty acid oxidation by inhibiting PPARA transcriptional activation. Impairs SIRT1:PPARA interaction probably through the regulation of NAD(+) levels (PubMed:24043310). Down-regulates insulin secretion.
Tissue specificityDetected in vascular smooth muscle and striated muscle. Detected in insulin-producing beta-cells in pancreas islets of Langerhans (at protein level). Widely expressed. Weakly expressed in leukocytes and fetal thymus.
Sequence similaritiesBelongs to the sirtuin family. Class II subfamily.
Contains 1 deacetylase sirtuin-type domain.
Cellular localizationMitochondrion matrix.
- Information by UniProt
- MGC130046 antibody
- MGC130047 antibody
- MGC57437 antibody
ab227930 has not yet been referenced specifically in any publications.